UNICREDIT BANK/CALL/MODERNA/80/0.1/18.09.24 | Market Closed - BOERSE MUENCHEN 15:40:31 2024-06-27 EDT | ||
| 4.08 EUR | -3.32% |
|
| Current month | -31.31% | ||
| 1 month | -49.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 4.08 | -3.32% |
| 24-06-26 | 4.22 | -22.28% |
| 24-06-25 | 5.43 | +0.74% |
| 24-06-24 | 5.39 | +3.65% |
| 24-06-21 | 5.2 | 0.00% |
Real-time BOERSE MUENCHEN
Last update June 27, 2024 at 03:40 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
UniCredit
|
| WKN | HD0P12 |
| ISIN | DE000HD0P122 |
| Date issued | 2023-11-13 |
| Strike | 80 $ |
| Maturity | 2024-09-18 (83 Days) |
| Parity | 10 : 1 |
| Emission price | 1.23 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.3 € |
|---|---|
| Lowest since issue | 1.11 € |
| Spread | 0.02 € |
| Spread % | 0.50% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
121.2
USD
Average target price
145.9
USD
Spread / Average Target
+20.36%
- Stock Market
- Warrants
- Warrant
